A Reexamination of the Costs of Medical R&D Regulation

Forum for Health Economics and Policy

Volumn 15, Issue 1, 2012, Pages 1-28

  Philipson, Tomas J ^a   Sun, Eric ^b   Goldman, Dana ^c   Jena, Anupam B ^d  

^a UNIVERSITY OF CHICAGO   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

medical innovation; pharmaceutical regulation

Indexed keywords

EID: 84928650363     PISSN: None     EISSN: 15589544     Source Type: Journal    
DOI: 10.1515/fhep-2012-0020     Document Type: Article

References (20)

1. Adams, C. and V. Brantner (2003) "New Drug Development: Estimating Entry from Human Clinical Trials," FTC Working Paper.
2. Becker, G. S., T. J. Philipson and R. R. Soares (2006) "The Quantity and Quality of Life and the Evolution of World Inequality," American Economic Review, 95:277-291.
3. Berndt, E., I. Cockburn and Z. Griliches (1996) "Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indixes for Antidepressant Drugs," Brookings Papers on Economic Activity, Microeconomics, 2:133-199.
4. Caves, R. E., M. D. Whinston, M. A. Hurwitz, A. Pakes and P. Temin (1991) "Patent Expiration, Entry, and Competition in the US Pharmaceutical Industry," Brookings Papers on Economic Activity, Microeconomics, 1:1-66.
5. Chen, R. Y., N. A. Accortt, A. O. Westfall, M. J. Mugavero, J. L. Raper, G. A. Cloud, B. K. Stone, J. Carter, S. Call, M. Pisu, J. Allison and M. S. Saag (2006) "Distribution of Health Care Expenditures for HIV-Infected Patients," Clinical Infectious Diseases, 42:1003-1010.
6. DiMasi, J. A. (2002) "The Value of Improving the Productivity of the Drug Development Process: Faster Times and Better Decisions," Pharmacoeconomics, 20(Suppl 3):1-10.
7. DiMasi, J. A., R. W. Hansen, H. G. Grabowski and L. Lasagna (1991) "Cost of Innovation in the Pharmaceutical Industry," Journal of Health Economics, 10:107-142.
8. DiMasi, J. A., R. W. Hansen and H. G. Grabowski (2003) "The Price of Innovation: New Estimates of Drug Development Costs," Journal of Health Economics, 22:151-185.
9. Frantz, S. T. (2003) "Why are Clinical Costs so High?," Nature Reviews Drug Discovery, 2:851.
10. Grabowski, H. G. and J. M. Vernon (1992) "Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act," Journal of Law and Economics, 32:331-350.
11. Hansen, R. W. (1979) (ed.) The Pharmaceutical Development Process: Estimates of Current Development Costs and Times and the Effects of Regulatory Changes. Lexington, MA: Lexington Books.
12. Lakdawalla, D. N., E. C. Sun, A. B. Jena, C. M. Reyes, D. P. Goldman and T. J. Philipson (2010) "An Economic Evaluation of the War on Cancer," Journal of Health Economics, 29:333-346.
13. Murphy, K. and R. Topel (2006) "The Value of Healthy and Longevity," The Journal of Political Economy, 114:871-904.
14. Nordhaus, W. (2003) "The Health of Nations: The Contribution of Improved Health to Living Standards." In: (K. Murphy and R. Topel, eds.) Measuring the Gains from Medical Research: An Economic Approach. Chicago, IL: University of Chicago Press.
15. Olson, M. K. (2009) "PDUFA and Initial U.S. Drug Launches," Michigan Telecommunication and Technology Law Review, 15:393-416.
16. Philipson, T. J. and A. B. Jena (2005) "Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs," Forum for Health Economics and Policy, 9(Article 3).
17. Philipson, T. J., E. Berndt, A. Gottschalk and E. C. Sun (2008) "Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts," Journal of Public Economics, 92: 1306-1325.
18. US Congress, O. O. T. A. (1993) Pharmaceutical R&D: Costs, Risks, and Rewards. Washington, DC: US Government Printing Office.
19. Wiggins, S. (1987) The Cost of Developing a New Drug. Washington, DC: Pharmaceutical Manufacturers' Association.
20. Woltman, H. R. (1989) "Reviewing the Bidding: R&D Costs and Profitability of New Chemical Entities," Journal of Research in Pharmaceutical Economics, 1:49-65.